PharmMapper server: A web server for potential drug target identification using pharmacophore mapping approach

Nucleic Acids Research

Volumn 38, Issue SUPPL. 2, 2010, Pages

  Liu, Xiaofeng ^a,b   Ouyang, Sisheng ^a   Yu, Biao ^b   Liu, Yabo ^b   Huang, Kai ^b   Gong, Jiayu ^b   Zheng, Siyuan ^c   Li, Zhihua ^b   Li, Honglin ^b   Jiang, Hualiang ^a,b  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; DRUG; LIGAND; PROTEIN;

ALGORITHM; ARTICLE; COMPUTER PREDICTION; DRUG RESEARCH; HIGH THROUGHPUT SCREENING; INFORMATION PROCESSING; INFORMATION SERVICE; PEPTIDE MAPPING; PHARMACOPHORE; PRIORITY JOURNAL; PROTEIN DATABASE; BINDING SITE; CHEMISTRY; COMPUTER INTERFACE; COMPUTER PROGRAM; DRUG DESIGN; DRUG EFFECTS; FACTUAL DATABASE; INTERNET;

ANTINEOPLASTIC AGENTS, HORMONAL; BINDING SITES; DATABASES, FACTUAL; DRUG DESIGN; INTERNET; LIGANDS; PHARMACEUTICAL PREPARATIONS; PROTEINS; SOFTWARE; TAMOXIFEN; USER-COMPUTER INTERFACE;

EID: 77954264038     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gkq300     Document Type: Article

References (41)

1. Hopkins,A.L. and Groom,C.R. (2002) The druggable genome. Nat. Rev. Drug Discov., 1, 727-730.
2. Overington,J.P., Al-Lazikani,B. and Hopkins,A.L. (2006) How many drug targets are there? Nat. Rev. Drug Discov., 5, 993-996.
3. Bajorath,J. (2008) Computational analysis of ligand relationships within target families. Curr. Opin. Chem. Biol., 12, 352-358.
4. Huang,C.M., Elmets,C.A., Tang,D.C., Li,F. and Yusuf,N. (2004) Proteomics reveals that proteins expressed during the early stage of Bacillus anthracis infection are potential targets for the development of vaccines and drugs. Genomics, Proteomics Bioinformatics, 2, 143-151.
5. Klebe,G. (2006) Virtual ligand screening: strategies, perspectives and limitations. Drug Discov. Today, 11, 580-594.
6. O'Connor,K.A. and Roth,B.L. (2005) Finding new tricks for old drugs: an efficient route for public-sector drug discovery. Nat. Rev. Drug Discov., 4, 1005-1014.
7. Keiser,M.J., Roth,B.L., Armbruster,B.N., Ernsberger,P., Irwin,J.J. and Shoichet,B.K. (2007) Relating protein pharmacology by ligand chemistry. Nat. Biotechnol., 25, 197-206.
8. Campillos,M., Kuhn,M., Gavin,A.C., Jensen,L.J. and Bork,P. (2008) Drug target identification using side-effect similarity. Science, 321, 263-266.
9. Bender,A., Young,D.W., Jenkins,J.L., Serrano,M., Mikhailov,D., Clemons,P.A. and Davies,J.W. (2007) Chemogenomic data analysis: prediction of small-molecule targets and the advent of biological fingerprint. Comb. Chem. High Throughput Screen., 10, 719-731.
10. Jacoby,E. (2006) Chemogenomics: drug discovery's panacea? Mol. Biosyst., 2, 218-220.
11. Mestres,J. (2004) Computational chemogenomics approaches to systematic knowledge-based drug discovery. Curr. Opin. Drug Discov. Devel., 7, 304-313.
12. Rognan,D. (2007) Chemogenomic approaches to rational drug design. Br. J. Pharmacol., 152, 38-52.
13. Savchuk,N.P., Balakin,K.V. and Tkachenko,S.E. (2004) Exploring the chemogenomic knowledge space with annotated chemical libraries. Curr. Opin. Chem. Biol., 8, 414-417.
14. Wuster,A. and Madan,B.M. (2008) Chemogenomics and biotechnology. Trends Biotechnol., 26, 252-258.
15. Hert,J., Keiser,M.J., Irwin,J.J., Oprea,T.I. and Shoichet,B.K. (2008) Quantifying the relationships among drug classes. J. Chem. Inf. Model., 48, 755-765.
16. Xie,L., Li,J., Xie,L. and Bourne,P.E. (2009) Drug discovery using chemical systems biology: identification of the protein-ligand binding network to explain the side effects of CETP inhibitors. PLoS Comput. Biol., 5, e1000387.
17. Li,H.L., Gao,Z.T., Kang,L., Zhang,H.L., Yang,K., Yu,K.Q., Luo,X.M., Zhu,W.L., Chen,K.X., Shen,J.H. et al. (2006) TarFisDock: a web server for identifying drug targets with docking approach. Nucleic Acids Res., 34, W219-224.
18. Gao,Z.T., Li,H.L., Zhang,H.L., Liu,X.F., Kang,L., Luo,X.M., Zhu,W.L., Chen,K.X., Wang,X.C. and Jiang,H.L. (2008) PDTD: a web-accessible protein database for drug target identification. BMC Bioinformatics, 9, 104.
19. Wolber,G. and Langer,T. (2005) LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters. J. Chem. Inf. Model., 45, 160-169.
20. Steindl,M., Schuster,D., Wolber,G., Laggner,C. and Langer,C. High throughput structure-based pharmacophore modeling as a basis for successful parallel virtual screening. J. Comput. Aided Mol. Des., 20, 703-715.
21. Wishart,D.S., Knox,C., Guo,A.C., Cheng,D., Shrivastava,S., Tzur,D., Gautam,B. and Hassanali,M. (2008) DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res., 36, D901-906.
22. Liu,T., Lin,Y., Wen,X., Jorissen,R.N. and Gilson,M.K. (2007) BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities. Nucleic Acids Res., 35, D198-201.
23. Wang,R., Fang,X., Lu,Y. and Wang,S. (2004) The PDBbind database: collection of binding affinities for protein-ligand complexes with known three-dimensional structures. J. Med. Chem., 47, 2977-2980.
24. Laskowski,R.A., Hutchinson,E.G., Michie,A.D., Wallace,A.C., Jones,M.L. and Thornton,J.M. (1997) PDBsum: a Web-based database of summaries and analyses of all PDB structures. Trends Biochem. Sci., 22, 488-490.
25. UniProt Consortium. (2007) The universal protein resource (UniProt). Nucleic Acids Res., 35, D193-197.
26. Sadowski,J. and Gasteiger,J. (1993) From atoms and bonds to 3-dimensional atomic coordinates - automatic model builders. Chem. Rev., 93, 2567-2581.
27. Sheridan,R.P., Rusinko,A., Nilakantan,R. and Venkataraghavan,R. (1989) Searching for pharmacophores in large coordinate data bases and its use in drug design. Proc. Natl Acad. Sci. USA., 86, 8165-8169.
28. Berman,H.M., Westbrook,J., Feng,Z., Gilliland,G., Bhat,T.N., Weissig,H., Shindyalov,I.N. and Bourne,P.E. (2000) The protein data bank. Nucleic Acids Res., 28, 235-242.
29. Hughes-Davies,L., Caldas,C. and Wishart,G.C. (2009) Tamoxifen: the drug that came in from the cold. Br. J. Cancer., 101, 875-878.
30. Favoni,R.E. and de Cupis,A. (1998) Steroidal and nonsteroidal oestrogen antagonists in breast cancer: basic and clinical appraisal. Trends Pharmacol. Sci., 19, 406-415.
31. Rowlands,M.G., Budworth,J., Jarman,M., Hardcastle,I.R., McCague,R. and Gescher,A. (1995) Comparison between inhibition of protein kinase C and antagonism of calmodulin by tamoxifen analogues. Biochem. Pharmacol., 50, 723-726.
32. Nilsson,U.W., Garvin,S. and Dabrosin,C. (2007) MMP-2 and MMP-9 activity is regulated by estradiol and tamoxifen in cultured human breast cancer cells. Breast Cancer Res. Treat., 102, 253-261.
33. Messiha,F.S. (1990) Leu-enkephalin, tamoxifen and ethanol interactions: effects on motility and hepatic ethanol metabolizing enzymes. Gen. Pharmacol., 21, 45-48.
34. Santner,S.J. and Santen,R.J. (1993) Inhibition of estrone sulfatase and 17beta-hydroxysteroid dehydrogenase by antiestrogens. J. Steroid Biochem. Mol. Biol., 45, 383-390.
35. Ritchie,G.A. (1980) The direct inhibition of prostaglandin synthetase of human breast cancer tumor tissue by tamoxifen. Recent Results Cancer Res., 71, 96-101.
36. Lax,E.R., Rumstadt,F., Plasczyk,H., Peetz,A. and Schriefers,H. (1983) Antagonistic action of estrogens, flutamide, and human growth hormone on androgen-induced changes in the activities of some enzymes of hepatic steroid metabolism in the rat. Endocrinology, 113, 1043-1055.
37. Nuwaysir,E.F., Daggett,D.A., Jordan,V.C. and Pitot,H.C. (1996) Phase II enzyme expression in rat liver in response to the antiestrogen tamoxifen. Cancer Res., 56, 3704-3710.
38. Levine,R.M., Rubalcaba,E., Lippman,M.E. and Cowan,K.H. (1985) Effects of estrogen and tamoxifen on the regulation of dihydrofolate reductase gene expression in a human breast cancer cell line. Cancer Res., 45, 1644-1650.
39. Paavonen,T., Aronen,H., Pyrhonen,S., Hajba,A. and Andersson,L.C. (1991) The effect of toremifene therapy on serum immunoglobulin levels in breast cancer. Apmis, 99, 849-853.
40. de-Médina,P., Favre,G. and Poirot,M. (2004) Multiple targeting by the antitumor drug tamoxifen: a structure-activity study. Curr. Med. Chem. Anticancer Agents, 4, 491-508.
41. Fleming,C.D., Bencharit,S., Edwards,C.C., Hyatt,J.L., Tsurkan,L., Bai,F., Fraga,C., Morton,C.L., Howard-Williams,E.L., Potter,P.M. et al. Structural insights into drug processing by human carboxylesterase 1: tamoxifen, mevastatin, and inhibition by benzil. J. Mol. Biol., 352, 165-177.